FrancophonIA/ELRC3.0 huggingface dataset:
English: Yarvitan has been studied in dogs in both laboratory and field trials.
Slovenian: Zdravilo Yarvitan je bilo preučeno na psih v laboratoriju in v preskusih na terenu.
English: Information on the prescription status of this product may be found on the label/outer package.
Slovenian: Podatki o predpisovanju tega zdravila so navedeni na notranji/zunanji ovojnini.
English: The active substance in Yarvitan, mitratapide, works in the gut by blocking a protein (the microsomal triglyceride transfer protein).
Slovenian: Zdravilna učinkovina v zdravilu Yarvitan, mitratapid, deluje v črevesju z blokiranjem beljakovine (mikrosomske prenašalne beljakovine za trigliceride).
English: What benefit has Yarvitan shown during the studies?
Slovenian: Kakšne koristi je zdravilo Yarvitan izkazalo med raziskavami?
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) YARVITAN EPAR summary for the public
Slovenian: EMEA/V/C/0113 EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) YARVITAN Povzetek EPAR za javnost
English: About three-quarters received Yarvitan while the remainder received the medicine with the active substance removed (control group).
Slovenian: Približno tri četrtine psov je prejemalo zdravilo Yarvitan, preostali psi pa so prejemali zdravilo brez zdravilne učinkovine (kontrolna skupina).
English: The dose to use is calculated according to the weight of the dog and the Yarvitan solution is given with the animal's food.
Slovenian: Uporabljeni odmerek se izračuna glede na telesno težo psa, nato pa se raztopina Yarvitan daje psu s hrano.
English: Yarvitan at the recommended dose and using the 3-2-3 week treatment schedule reduced body weight in obese dogs when compared to the control group.
Slovenian: Zdravilo Yarvitan je v priporočenem odmerku in ob uporabi urnika zdravljenja 3-2-3 tedne znižalo telesno težo debelih psov v primerjavi s kontrolno skupino.
English: Yarvitan also has a slight appetite decreasing effect due to its mode of action.
Slovenian: Zdravilo Yarvitan ima zaradi svojega načina delovanja tudi šibek učinek zmanjšanja apetita.
English: Yarvitan is an oral solution, colourless to slightly yellow in colour.
Slovenian: Zdravilo Yarvitan je brezbarvna do rahlo rumena peroralna raztopina.
English: Yarvitan contains the active substance mitratapide which helps to reduce weight in dogs.
Slovenian: Zdravilo Yarvitan vsebuje zdravilno učinkovino mitratapid, ki pripomore k znižanju telesne teže psov.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Yarvitan exceed its risks for the management of overweight and obesity in dogs and recommended that Yarvitan be given a marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristi zdravila Yarvitan pri obravnavi prekomerne telesne teže in debelosti psov večje od z njim povezanih tveganj, zato priporoča odobritev dovoljenja za promet z zdravilom Yarvitan.
English: Vomiting, diarrhoea or softened faeces may occur during treatment.
Slovenian: Med zdravljenjem lahko pride do bruhanja, driske ali mehkejših iztrebkov.
English: What is Yarvitan used for?
Slovenian: Za kaj se zdravilo Yarvitan uporablja?
English: A reduced appetite may also occur during treatment.
Slovenian: Med zdravljenjem se lahko apetit psa zmanjša.
English: The medicine is administered to the dog for 3 weeks, followed by a 2-week medicine-free interval, when the veterinarian will adjust the dog's feeding according to its energy requirements.
Slovenian: Temu sledi dvotedenska prekinitev, ko veterinar prehrano psa prilagaja energijskim potrebam psa.
English: Why has Yarvitan been approved?
Slovenian: Zakaj je bilo zdravilo Yarvitan odobreno?
English: How has Yarvitan been studied?
Slovenian: Kako je bilo zdravilo Yarvitan raziskano?
English: What is the risk associated with Yarvitan?
Slovenian: Kakšna tveganja so povezana z zdravilom Yarvitan?
English: This protein is normally involved in the absorption of fats from the diet. By blocking the protein Yarvitan decreases the absorption of fats from the gut.
Slovenian: Ko zdravilo Yarvitan blokira beljakovino, se absorpcija maščob iz črevesja zmanjša.
English: How does Yarvitan work?
Slovenian: Kako zdravilo Yarvitan deluje?
English: The treatment is an initial measure in an obesity management programme; it has to be combined with changes in diet, which must be continued after treatment is finished.
Slovenian: Zdravilo je treba kombinirati s spremembo prehrane.
English: For a full list of all side-effects reported with Yarvitan, see the Package Leaflet.
Slovenian: Celovit opis neželenih učinkov, o katerih so poročali pri uporabi zdravila Yarvitan, najdete v Navodilih za uporabo.
English: Yarvitan is used in adult dogs that are overweight or obese, to help them lose weight.
Slovenian: Zdravilo Yarvitan se uporablja za nižanje telesne teže odraslih psov, ki imajo prekomerno telesno težo oz. so debeli.
English: 700 mg Film-coated tablets
Slovenian: 700 mg Filmsko obložene tablete Peroralna uporaba
English: Bottle (HDPE) 225 ml
Slovenian: Steklenička (HDPE) 225 ml
English: EU number
Slovenian: Vsebina
English: 50 mg/ml Oral suspension
Slovenian: 50 mg/ml Peroralna suspenzija Peroralna uporaba
English: 1 bottle + 10 ml dosing syringe
Slovenian: 1 steklenička + brizga za odmerjanje 10 ml
English: Invented name Strength Pharmaceutical form Route of administration Packaging Content
Slovenian: Številka EU Zaščiteno ime Jakost Farmacevtska oblika Način uporabe zdravila Ovojnina
English: (Invented) name Strength
Slovenian: Izmišljeno ime
English: EMEA Number
Slovenian: Številka EU
English: Pharmaceutical Form Route of Administration Packaging Package size l t o r
Slovenian: Velikost pakiranja o ā
English: --1 Influenza A/eq/Ohio/03 [H3N8] recombinant canarypox virus (vCP2242) ≥ 5.3 log10 FAID50*/ml Influenza A/eq/Richmond/1/07 [H3N8] recombinant canarypox virus (vCP3011) ≥ 5.3 log10 FAID50*/ml * vCP content checked by global FAID50 (fluorescent assay infectious dose 50%) and qPCR ratio between vCP.
Slovenian: --1 Influenza A/eq/ Ohio/03 [H3N8] rekombinantni canarypox virus (vCP2242) ≥ 5,3 log10 FAID50*/ml Influenza A/eq/Richmond/1/07 [H3N8] rekombinantni canarypox virus (vCP1533) ≥ 5,3 log10 FAID50*/ml
English: Horses Intramuscular use Vial (glass) 1 ml
Slovenian: Intramuskularno Viala (steklo) 1 ml
English: Target Species
Slovenian: Ciljna živalska vrsta
English: Packaging Content Package Size
Slovenian: Ovojnina Vsebina Velikost pakiranja
English: EU (MA) Number Invented name
Slovenian: EU (MA) Številka
English: Strength Pharmaceutical Form
Slovenian: Farmacvtska oblika
English: Further information on Fulphila can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/fulphila.
Slovenian: Več informacij o zdravilu Fulphila je na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/fulphila.
English: Pain in muscles is also common.
Slovenian: Pogoste so tudi bolečine v mišicah.
English: This slows down the removal of filgrastim from the body, allowing the medicine to be given less often.
Slovenian: To upočasni odstranjevanje filgrastima iz telesa, zato se zdravilo lahko daje manj pogosto.
English: This means that Fulphila is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Slovenian: To pomeni, da je zelo podobno drugemu biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v EU.
English: Neutropenia lasted 1 day on average with both medicines.
Slovenian: Pri obeh zdravilih je nevtropenija trajala povprečno en dan.
English: What measures are being taken to ensure the safe and effective use of Fulphila?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Fulphila?
English: The most common side effect with Fulphila (which may affect more than 1 in 10 people) is pain in the bones.
Slovenian: Najpogostejši neželeni učinek zdravila Fulphila (ki se lahko pojavi pri več kot 1 bolniku od 10) je bolečina v kosteh.
English: An overview of Fulphila and why it is authorised in the EU
Slovenian: Pregled zdravila Fulphila in zakaj je odobreno v EU
English: It is available as a prefilled syringe containing a solution for injection under the skin.
Slovenian: Na voljo je v obliki napolnjene injekcijske brizge, ki vsebuje raztopino za injiciranje pod kožo.
English: Side effects reported with Fulphila are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Fulphila, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: For more information about using Fulphila, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Fulphila glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: As for all medicines, data on the use of Fulphila are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Fulphila stalno spremljajo.
English: Fulphila is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines).
Slovenian: Zdravilo Fulphila se daje v obliki enkratnega odmerka v jakosti 6 mg, ki se injicira pod kožo vsaj 24 ur po koncu vsakega ciklusa kemoterapije (zdravljenja z zdravili proti raku).
English: What benefits of Fulphila have been shown in studies?
Slovenian: Kakšne koristi zdravila Fulphila so se pokazale v študijah?
English: Why is Fulphila authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Fulphila odobreno v EU?
English: Other information about Fulphila
Slovenian: Druge informacije o zdravilu Fulphila
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fulphila have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Fulphila upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Fulphila can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders.
Slovenian: Predpisovanje in izdaja zdravila je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem rakavih obolenj ali krvnih bolezni.
English: It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever).
Slovenian: Zdravilo se daje za skrajševanje trajanja nevtropenije in preprečevanje febrilne nevtropenije (nevtropenije, ki jo spremlja povišana telesna temperatura).
English: The reference medicine for Fulphila is Neulasta.
Slovenian: Referenčno zdravilo za zdravilo Fulphila je zdravilo Neulasta.
English: Filgrastim works by encouraging the bone marrow to produce more white blood cells, increasing white blood cell counts and so treating neutropenia.
Slovenian: Filgrastim deluje tako, da spodbuja kostni mozeg k proizvodnji več belih krvnih celic, s čimer poveča število belih krvnih celic in zdravi nevtropenijo.
English: What are the risks associated with Fulphila?
Slovenian: Kakšna tveganja so povezana z zdravilom Fulphila?
English: What is Fulphila and what is it used for?
Slovenian: Kaj je zdravilo Fulphila in za kaj se uporablja?
English: All these data were considered sufficient to conclude that Fulphila will behave in the same way as Neulasta in terms of effectiveness and safety in its authorised uses.
Slovenian: Vsi ti podatki so bili ocenjeni kot zadostni za zaključek, da se bo zdravilo Fulphila pri odobrenih uporabah z vidika učinkovitosti in varnosti vedlo enako kot zdravilo Neulasta.
English: The safety of Fulphila has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Neulasta.
Slovenian: Varnost zdravila Fulphila je bila ocenjena in na podlagi vseh izvedenih študij so bili neželeni učinki zdravila ocenjeni kot primerljivi z neželenimi učinki referenčnega zdravila Neulasta.
English: The active substance in Fulphila, pegfilgrastim, is a form of filgrastim, which is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).
Slovenian: Učinkovina zdravila Fulphila, pegfilgrastim, je sestavljena iz filgrastima, ki je zelo podoben človeški beljakovini, imenovani granulocitne kolonije spodbujajoči faktor (G-CSF).
English: Because Fulphila is a biosimilar medicine, the studies on effectiveness and safety of pegfilgrastim carried out with Neulasta do not all need to be repeated for Fulphila.
Slovenian: Zdravilo Fulphila je podobno biološko zdravilo, zato študij o učinkovitosti in varnosti pegfilgrastima, izvedenih z zdravilom Neulasta, z zdravilom Fulphila ni treba ponavljati.
English: In addition, a study involving 194 patients who had chemotherapy before or after surgery for breast cancer showed that Fulphila was as effective as Neulasta in reducing the duration of neutropenia.
Slovenian: Poleg tega so v študiji, ki je vključevala 194 bolnic, ki so se s kemoterapijo zdravile pred kirurškim posegom zaradi raka dojk ali po njem, dokazali, da je zdravilo Fulphila pri skrajševanju trajanja nevtropenije enako učinkovito kot zdravilo Neulasta.
English: Fulphila is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia).
Slovenian: Zdravilo Fulphila ni namenjeno uporabi pri bolnikih s krvnim rakom, tj. kronično mieloično levkemijo ali mielodisplastičnimi sindromi (boleznimi, pri katerih nastajajo velike količine nenormalnih krvnih celic, ki se lahko razvijejo v levkemijo).
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Fulphila has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way.
Slovenian: Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Fulphila po zgradbi, čistosti in biološkem delovanju primerljivo zdravilu Neulasta in da se po telesu enako prenaša.
English: For the full list of side effects and restrictions with Fulphila, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Fulphila glejte navodilo za uporabo.
English: Fulphila is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections.
Slovenian: Fulphila je zdravilo, ki se uporablja pri bolnikih z rakom za pomoč pri nevtropeniji (zmanjšanem številu nevtrofilcev, vrste belih krvnih celic), ki je pogost neželeni učinek pri zdravljenju raka, zaradi katerega pa so bolniki dovzetnejši za okužbe.
English: In addition, studies in breast cancer patients undergoing chemotherapy have shown that the effectiveness of Fulphila is equivalent to that of Neulasta in reducing the duration of neutropenia.
Slovenian: Poleg tega so v študijah pri bolnicah z rakom dojke, ki so se zdravile s kemoterapijo, dokazali, da je učinkovitost zdravila Fulphila pri skrajševanju trajanja nevtropenije enakovredna učinkovitosti zdravila Neulasta.
English: Fulphila is a ‘biosimilar medicine'.
Slovenian: Zdravilo Fulphila je „podobno biološko zdravilo“.
English: In Fulphila, filgrastim has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Slovenian: V zdravilu Fulphila je filgrastim „pegiliran“ (vezan na kemično snov, imenovano polietilenglikol).
English: Therefore, the Agency's view was that, as for Neulasta, the benefit of Fulphila outweighs the identified risk and it can be authorised for use in the EU.
Slovenian: Agencija je menila, da koristi zdravila Fulphila enako kot pri zdravilu Neulasta odtehtajo znana tveganja in da se zdravilo lahko odobri v EU.
English: How does Fulphila work?
Slovenian: Kako zdravilo Fulphila deluje?
English: Laboratory studies comparing Fulphila with Neulasta have shown that the active substance in Fulphila is highly similar to that in Neulasta in terms of structure, purity and biological activity.
Slovenian: Laboratorijske študije, v katerih so zdravilo Fulphila primerjali z zdravilom Neulasta, so pokazale, da je učinkovina zdravila Fulphila po zgradbi, čistosti in biološkem delovanju zelo podobna učinkovini v zdravilu Neulasta.
English: How is Fulphila used?
Slovenian: Kako se zdravilo Fulphila uporablja?
English: Studies have also shown that giving Fulphila produces similar levels of the active substance in the body to giving Neulasta.
Slovenian: Študije so pokazale tudi, da zdravilo Fulphila vzpostavi podobne ravni učinkovine v telesu kot zdravilo Neulasta.
English: The full EPAR for Clopidogrel Apotex can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za Clopidogrel Apotex je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Clopidogrel Apotex clopidogrel
Slovenian: Clopidogrel Apotex klopidogrel
English: It is used in those patients who have at least one risk factor for vascular events such as a heart attack or stroke, cannot take vitamin K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.
Slovenian: Uporablja se pri tistih bolnikih, pri katerih obstaja vsaj en dejavnik tveganja za vaskularne dogodke, kot sta srčni napad ali kap, ki ne morejo jemati antagonistov vitamina K (drugih zdravil za preprečevanje krvnih strdkov) in pri katerih je tveganje za krvavitev majhno.
English: Previously known as Clopidogrel Mylan Pharma.
Slovenian: 1 Prej znano kot Clopidogrel Mylan Pharma.
English: In acute coronary syndrome and atrial fibrillation, Clopidogrel Apotex is used together with aspirin, the dose of which should not be higher than 100 mg.
Slovenian: Pri akutnem koronarnem sindromu in atrijski fibrilaciji se zdravilo Clopidogrel Apotex uporablja skupaj z aspirinom, katerega odmerek ne sme biti višji od 100 mg.
English: This document is a summary of the European Public Assessment Report (EPAR) for Clopidogrel Apotex.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Clopidogrel Apotex.
English: For more information about treatment with Clopidogrel Apotex, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Clopidogrel Apotex preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: In acute coronary syndrome, treatment generally starts with a loading dose of four 75-mg tablets.
Slovenian: Pri akutnem koronarnem sindromu se zdravljenje na splošno začne z udarnim odmerkom štirih 75-miligramskih tablet.
English: This means that Clopidogrel Apotex is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Plavix.
English: The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel Mylan Pharma on 16 October 2009.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Clopidogrel Mylan Pharma, veljavno po vsej Evropski uniji, odobrila dne 16. oktobra 2009.
English: The name of the medicine was changed to Clopidogrel Apotex on 20 January 2010.
Slovenian: Ime zdravila je bilo 20. januarja 2010 spremenjeno v Clopidogrel Apotex.
English: Clopidogrel Apotex is used to prevent problems caused by blood clots in adults who have:
Slovenian: Zdravilo Clopidogrel Apotex se uporablja za preprečevanje težav, ki jih povzročajo krvni strdki pri odraslih, ki:
English: The standard dose of Clopidogrel Apotex is one 75-mg tablet once a day.
Slovenian: Običajni odmerek zdravila Clopidogrel Apotex je ena 75-miligramska tableta enkrat dnevno.
English: Clopidogrel Apotex can be started between a few days and 35 days after the attack;
Slovenian: Zdravilo Clopidogrel Apotex se lahko začne jemati nekaj dni po napadu in do 35 dni po njem;
English: Because Clopidogrel Apotex is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Slovenian: Ker je zdravilo Clopidogrel Apotex generično zdravilo in je biološko enakovredno referenčnemu zdravilu, šteje, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: • atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin.
Slovenian: • imajo atrijsko fibrilacijo (neredno in hitro krčenje zgornjih preddvorov srca), pri katerem se mora zdravilo dajati skupaj z aspirinom.
English: The Committee recommended that Clopidogrel Apotex be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Clopidogrel Apotex odobri dovoljenje za promet.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel Apotex.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Clopidogrel Apotex, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Other information about Clopidogrel Apotex:
Slovenian: Druge informacije o zdravilu Clopidogrel Apotex:
English: Clopidogrel Apotex can be started between seven days and six months after the stroke;
Slovenian: Zdravilo Clopidogrel Apotex se lahko začne jemati od sedem dni po kapi in do šest mesecev po njej;
English: Because Clopidogrel Apotex is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Slovenian: Ker je zdravilo Clopidogrel Apotex generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Plavix.
English: The CHMP concluded that, in accordance with EU requirements, Clopidogrel Apotex has been shown to have comparable quality and to be bioequivalent to Plavix.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Clopidogrel Apotex primerljivo raven kakovosti kot zdravilo Plavix ter da mu je biološko enakovredno.
English: What are the benefits and risks of Clopidogrel Apotex?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Clopidogrel Apotex?
English: include heart attacks and unstable angina (a severe type of chest pain).
Slovenian: Akutni koronarni sindrom je skupina obolenj srca, ki zajema tudi srčni napad in nestabilno angino pektoris (hudo obliko bolečine v prsih).
English: Clopidogrel Apotex is a medicine that contains the active substance clopidogrel.
Slovenian: Clopidogrel Apotex je zdravilo, ki vsebuje zdravilno učinkovino klopidogrel.
English: Clopidogrel Apotex is a ‘generic medicine'.
Slovenian: Zdravilo Clopidogrel Apotex je „generično zdravilo“.
English: The active substance in Clopidogrel Apotex, clopidogrel, is an inhibitor of platelet aggregation.
Slovenian: Zdravilna učinkovina v zdravilu Clopidogrel Apotex, klopidogrel, je zaviralec agregacije trombocitov.
English: Why has Clopidogrel Apotex been approved?
Slovenian: Zakaj je bilo zdravilo Clopidogrel Apotex odobreno?
English: How has Clopidogrel Apotex been studied?
Slovenian: Kako je bilo zdravilo Clopidogrel Apotex raziskano?
English: What is Clopidogrel Apotex?
Slovenian: Kaj je zdravilo Clopidogrel Apotex?